Table 1.

Patient demographics and baseline characteristics

	Total Cohort		PCI Administered		PCI Not Administered		P-valuea
	n	%	n	%	n	%
Patients	208		115	55	93	45
Median age (range), years	67 (43-94)		63 (44-85)		71 (46-94)		<.001
Median KPS (range)	90 (40-100)		90 (60-100)		80 (40-100)		.004
KPS ≤70	29	14	7	24	22	76
Sex							.121
Female	119	57	71	60	48	40
Male	90	43	44	49	45	50
Clinical AJCC stage							.067
IA	22	11	6	27	16	73
IB	9	4	3	33	6	67
IIA	30	14	18	60	12	40
IIB	12	6	7	58	5	42
IIIA	94	45	55	59	39	41
IIIB	41	20	26	63	15	37
Thoracic RT							<.001
Yes	181	87	109	60	72	40
No (surgical resection only)	27	13	6	22	21	78
Thoracic RT fractionation							<.001
BID	104	50	74	71	30	29
QD	77	37	35	45	42	55
Chemotherapy timing with thoracic RT							<.001
Concurrent	143	69	100	70	43	30
Sequential (pre-RT)	38	18	15	39	50	32
PCIb
Median dose (IQR), Gy	25.0 (25.0-31.0)
10 fractions	63	30%
12-13 fractions	3	1%
15 fractions	46	22%

AJCC, American Joint Committee on Cancer; BID, twice per day; IQR, interquartile range; KPS, Karnofsky performance status; PCI, prophylactic cranial irradiation; QD, once per day; RT, radiation therapy.

^aIndependent-samples Mann-Whitney U test was performed for age, KPS, and thoracic RT dose. χ² test was performed for all other variables.

^bA total of 112 of 115 patients with available fraction number and dose.